SRCM
STLNW

Sage Rock Capital Management’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Sage Rock Capital Management’s Portfolio STLNW Stock Details STLNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-255,489
Closed -$345K – 224
2021
Q1 		$345K Hold
255,489
– – 0.04% 190
2020
Q4 		$498K Buy
+255,489
New +$441K 0.08% 101

Other funds holding STLNW

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Sage Rock Capital Management's STLNW Position: Q2 2021 in Review

Sage Rock Capital Management sold out of Starling Oncology, Inc. Warrant (STLNW) in Q2 2021, closing a stake of 255,489 shares — an estimated $345K sold.

Sage Rock Capital Management first reported a position in STLNW in Q4 2020 and held it in 2 quarters. The position peaked at $498K in Q4 2020. 26 funds tracked by Wall St. Rank hold STLNW as of Q2 2021.

  • Sage Rock Capital Management reported no remaining Starling Oncology, Inc. Warrant position as of Q2 2021 after selling out during the quarter.
  • Sage Rock Capital Management sold 255,489 Starling Oncology, Inc. Warrant shares in Q2 2021, an estimated $345K.
  • Sage Rock Capital Management first reported a position in Starling Oncology, Inc. Warrant in Q4 2020 and held it in 2 quarters.
  • Sage Rock Capital Management's Starling Oncology, Inc. Warrant position peaked at $498K in Q4 2020.
  • 26 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q2 2021.

Based on Sage Rock Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.